格隆汇9月25日丨海正生材(688203.SH)公布，因经营发展资金需求，中石化资本计划拟自本公告披露之 日起十五个交易日后的三个月内，通过集中竞价交易方式减持不超过202.67万股，占公司总股本比例不 超过1%。上述股份减持价格按减持实施时的市场价格确定。 ...

Core Viewpoint - China Petroleum Capital Holdings Co., Ltd. plans to reduce its stake in Haizheng Biomaterials by selling up to 2.0267 million shares, representing a maximum reduction of 1% of the total shares held [1] Group 1 - The company currently holds 12.8149 million shares, which accounts for 6.32% of the total shares [1] - The planned reduction will take place within three months, starting from October 28, 2025, to January 27, 2026 [1] - The shares to be sold are sourced from those acquired prior to the company's IPO [1]

Group 1 - The core viewpoint of the news is that Zhejiang Haizheng Biological Materials Co., Ltd. has experienced a significant decline in stock price, with a drop of 5.07% on September 19, bringing the total market value to 2.923 billion yuan and a cumulative decline of 7.72% over three consecutive days [1] - The company specializes in the research, production, and sales of polylactic acid, with its main business revenue composition being 78.55% from pure polylactic acid, 20.50% from modified polylactic acid, and 0.96% from other sources [1] - The stock's trading volume on the reporting day was 56.7391 million yuan, with a turnover rate of 3.08% [1] Group 2 - According to data from the top ten circulating shareholders, GF Fund's Guangfa Technology Innovation Mixed A Fund has entered the top ten shareholders, holding 7.0478 million shares, which accounts for 5.99% of the circulating shares [2] - The fund has incurred a floating loss of approximately 5.4268 million yuan today and a total floating loss of 8.9507 million yuan during the three-day decline [2] - Guangfa Technology Innovation Mixed A Fund has achieved a year-to-date return of 56.06% and a one-year return of 108.31%, ranking 687 out of 8172 and 428 out of 7980 in its category, respectively [2]

Group 1 - The core viewpoint of the news is that Zhejiang Haizheng Biomaterials Co., Ltd. has seen a stock price increase of 5.72%, reaching 16.83 CNY per share, with a total market capitalization of 3.41 billion CNY [1] - The company specializes in the research, production, and sales of polylactic acid, with its main revenue sources being pure polylactic acid (78.55%), modified polylactic acid (20.50%), and others (0.96%) [1] - The trading volume for the stock was 95.70 million CNY, with a turnover rate of 4.82% [1] Group 2 - According to data, GF Fund's Guangfa Technology Innovation Mixed A Fund (008638) has entered the top ten circulating shareholders of Haizheng Biomaterials, holding 7.05 million shares, which is 5.99% of the circulating shares [2] - The fund has achieved a year-to-date return of 51.91%, ranking 749 out of 8246 in its category, and a one-year return of 99.24%, ranking 499 out of 8054 [2] - The fund's total scale is 2.657 billion CNY, and since its inception, it has returned 136.12% [2] Group 3 - The fund manager of Guangfa Technology Innovation Mixed A is Wu Yuanyi, who has been in the position for 4 years and 352 days [3] - Under Wu's management, the fund's total asset scale is 20.478 billion CNY, with the best return during his tenure being 107.14% and the worst being -15.24% [3]

Company Overview - Zhejiang Haizheng Biomaterials Co., Ltd. is located in Taizhou Bay New District, Zhejiang Province, and was established on August 26, 2004. The company went public on August 16, 2022. Its main business involves the research, production, and sales of polylactic acid (PLA) [1] - The revenue composition of the company includes 78.55% from pure polylactic acid, 20.50% from modified polylactic acid, and 0.96% from other sources [1] Stock Performance - On September 8, Haizheng Biomaterials' stock rose by 5.06%, reaching a price of 17.02 yuan per share, with a trading volume of 110 million yuan and a turnover rate of 5.61%. The total market capitalization is 3.45 billion yuan [1] Shareholder Information - According to data, one of the top ten circulating shareholders of Haizheng Biomaterials is the Guangfa Technology Innovation Mixed Fund A (008638), which entered the top ten in the second quarter with 7.05 million shares, accounting for 5.99% of the circulating shares. The estimated floating profit today is approximately 5.78 million yuan [2] - Guangfa Technology Innovation Mixed Fund A was established on December 25, 2019, with a latest scale of 2.657 billion yuan. Year-to-date returns are 42.42%, ranking 1002 out of 8248 in its category; the one-year return is 79.57%, ranking 755 out of 8051; and since inception, the return is 121.36% [2]

中信建投证券股份有限公司 关于浙江海正生物材料股份有限公司 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | | 东、实际控制人等未履行承诺事项的，及 | 况 | | | 时向上海证券交易所报告。 | | | | 关注公共传媒关于上市公司的报道，及时 | | | | 针对市场传闻进行核查。经核查后发现上 | | | | 市公司存在应披露未披露的重大事项或与 | 2025 年 1-6 月，经保荐机构核查，海正 | | 13 | 披露的信息与事实不符的，应及时督促上 | 生材不存在应及时向上海证券交易所 | | | 市公司如实披露或予以澄清；上市公司不 | 报告的情况 | | | 予披露或澄清的，应及时向上海证券交易 | | | | 所报告 。 | | | | 发现以下情形之一的，保荐机构应督促上 | | | | 市公司做出说明并限期改正，同时向上海 | | | | 证券交易所报告：（一）上市公司涉嫌违 | | | | 反《上市规则》等上海证券交易所相关业 | | | | 务规则；（二）证券服务机构及其签名人 | | | | 员出具的专业意见可能存在虚假记载、误 | 202 ...

Group 1 - The stock of Hai Zheng Sheng Cai (688203) closed at 16.66 yuan on September 1, reaching the daily limit with a trading volume of 2.01 billion yuan and a turnover rate of 10.03% [2] - The stock was listed on the trading board due to a price increase of 15% at the close of the day [2] - The top five trading departments accounted for a total transaction amount of 1.11 billion yuan, with net buying of 309.56 million yuan [2][3] Group 2 - The main capital inflow for the stock was 42.64 million yuan throughout the day [3] - The largest buying department was Huaxin Securities, with a purchase amount of 24.99 million yuan, followed by Kaiyuan Securities with 20.42 million yuan [3] - The selling departments included CITIC Securities with a sale amount of 16.66 million yuan and an institutional special seat selling 7.28 million yuan [3]

Group 1 - The company, Haizheng Shengcai, announced that as of August 31, 2025, it has repurchased a total of 1,637,364 shares through the Shanghai Stock Exchange trading system, representing 0.808% of the company's current total share capital [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：688203 证券简称：海正生材 公告编号：2025-50 浙江海正生物材料股份有限公司 关于股份回购进展公告 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，上市公司应当在每个月的前 3 个交易日内公告截 至上月末的回购进展情况。现将公司回购股份的进展情况公告如下： 截至 2025 年 8 月 31 日，公司通过上海证券交易所交易系统以集中竞价交易 方式已累计回购公司股份 1,637,364 股，占公司目前总股本 202,678,068 股的比 例为 0.808%，回购成交的最高价为 14.63 元/股，最低价为 7.76 元/股，支付的资 金总额为人民币 16,482,602.36 元（不含印花税、交易佣金等交易费用）。 公司本次回购股份符合相关法律法规及公司回购股份方案的规定。 重要内容提示： | 回购方案首次披露日 | 2024/8/29 | | | | | | | | --- | -- ...

Group 1 - The company, Haizheng Shengcai, announced a share buyback of approximately 1.64 million shares, representing 0.808% of its total share capital of about 203 million shares, with a total expenditure of approximately 16.48 million RMB [1] - The highest and lowest prices for the repurchased shares were 14.63 RMB and 7.76 RMB per share, respectively [1] - For the year 2024, the company's revenue composition indicates that the fiber manufacturing industry accounts for 98.77% of its total revenue, while other businesses contribute 1.23% [1] Group 2 - As of the latest report, the market capitalization of Haizheng Shengcai is 3.4 billion RMB [2]